VyWhy listed the best 20 results for Why did pfizer stock drop as below
20 results, recently updated
21-12-2021 · When COVID-19 fears decrease, Pfizer's shares are more likely to fall. That's because the company generates a significant portion of its revenue from COVID-19 vaccine sales. While other leading...
Shares of Pfizer ( PFE -0.39% ) were sinking 4.4% as of 11:18 a.m. ET on Tuesday. The big drugmaker didn't report any new developments. Today's decline appears to be a by-product of the overall market rising after a pullback in recent days due to concerns about the spread of the coronavirus omicron variant.
When COVID-19 fears decrease, Pfizer's shares are more likely to fall. That's because the company generates a significant portion of its revenue from COVID-19 vaccine sales. While other leading vaccine stocks were also sliding today, Pfizer was hit the hardest -- probably because its shares have risen the most over the past few weeks.
Image source: Getty Images.
The reality is that little has changed in the expectations about the impact of the omicron variant since Monday when Pfizer's shares rose while many stocks were dropping. As such, little has changed about Pfizer's prospects. Today's move is probably more noise than anything else.
What isn't noise, though, is that the European Commission just exercised its option to buy another 200 million doses of Pfizer's and BioNTech's COVID-19 vaccine for delivery in 2022. The two companies announced the deal yesterday.
Investors will definitely want to monitor how the efficacy of Pfizer's vaccine with a booster dose fares against the omicron variant. If the efficacy wanes, it could lead to new orders for the omicron-specific vaccine version that Pfizer and BioNTech are developing.
In the meantime, Pfizer anticipates regulatory decisions in the near future for its COVID-19 pill Paxlovid. The oral therapy should be another huge commercial success for Pfizer beginning in 2022.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.
Proponents were pleased with the news, but shortly after Tai's announcement, stocks of pharmaceutical companies that have produced vaccines, including Moderna and Pfizer, plummeted. I seems the Biden administration has decided to throw its weight behind a patent waiver on Covid vaccines. This is what it's doing to the vaccine makers' share ...
Alena Yildiz said the bride, a close friend, saw a video of her in the bridesmaid dress and called her to say it was too "attention-grabbing."
The Omicron variant of COVID-19 has surged worldwide in record time—it was only three weeks ago that the first case was identified in South Africa. Last week, it accounted for 73% of new COVID infections in the United States, according to the latest CDC data. It's highly contagious—scientists estimate it's twice as transmissible as the Delta variant, which itself was twice as transmissible as the original COIVD strain—which calls for an abundance of caution. How do you know if you've been infect
- Why this Ad?
- Go ad-free
Get best practices to help your organization successfully shift to hybrid work
"When they could be a character in a 2005 RomCon, that's a red flag..."View Entire Post ›
A Minnesota jury has found former Brooklyn Center police officer Kim Potter guilty of first-degree and second-degree manslaughter in the shooting of Daunte Wright. Despite […]
Valley News Live via YouTubeWhen relatives hadn’t heard from the seven members of the Hernandez family for a few days, they asked authorities in Minnesota do a wellness check on Saturday night.What police discovered shocked the community of Moorhead, a small city on the North Dakota border, to the core: all seven family members, ranging in age from 37 to 7, were lying dead in their beds in the duplex home.“I went to the floor above and I entered into the room and all the family was together,” Er
- Why this Ad?
- Go ad-free
Everyone knows they should consult a financial advisor for retirement planning, but how do you choose which one? This free tool makes it simple.
Oakland County's prosecutor says the parents of Oxford school shooting suspect knew for months that their son was depressed but failed to get him help.
Trump stayed silent for over three hours after his supporters stormed the Capitol. The January 6 committee is trying to understand why.
"I am who I am. I’m good with it. You might need to figure it out, but I’m fine with it."View Entire Post ›
How Much Should A Full Set Of Dental Implants Cost In 2021?
Ciara‘s tiny figure was a topic of conversation on Dec. 20 after the singer shared a beach photo at an undisclosed location. In the Instagram […]
Steph Curry was determined to take a 3-pointer on this possession.
It's the largest animal found from that time period, both in the sea and on land, and currently holds the title of first giant animal to ever inhabit Earth.
- Ad•Google Fi
- Why this Ad?
- Go ad-free
Your private conversations stay private. Shop Pixel 6 on Fi and enjoy secure one-on-one calls between Android phones on Fi.
The Selling Sunset star announced his split from the model on Tuesday, the same day his twin brother announced his own breakup from Chrishell Stause
Charlene Rubush solved the puzzle — and that's when the outrage started.
A registered sex offender is facing a new set of charges after police caught him raping an Asian woman at a Manhattan construction site on Wednesday. The scene: New York police had to physically pull Darryl Phelps, 61, off the woman at around 1:30 a.m. under scaffolding at a construction site on West 28th Street near Eighth Avenue in Chelsea. The victim said she was walking home when Phelps punched her face, the New York Daily News reported.
- Why this Ad?
- Go ad-free
Board certified internal medicine and obesity specialist reveals the importance of breakfast and the 3 'health foods' you should avoid at all costs.
Bold predictions for the Cotton Bowl!
'Hulk' star Mark Ruffalo once revealed to Andy Cohen that he and his '13 Going on 30' costar Jennifer Garner stopped being close friends after the 2004 movie was released.
A Minneapolis jury reached an "outcome" in the trial of Kim Potter, a former police officer charged with fatally shooting Daunte Wright, a Black motorist.
Washington drivers are surprised they never knew this new tip. If you live in Washington, you better read this.
Coach Dan Mullen entered his fourth year at Florida eager to make the next step. By Thursday night’s Gasparilla Bowl against UCF, the season couldn’t end fast enough for the Gators. Other than bragging rights against UCF and personal pride, little was at stake for Florida during a 29-17 loss at Tampa’s Raymond James Stadium. Mullen and two top assistants were long gone. Sacks leader Zachary ...
Washington safety Deshazor Everett was the driver in a car crash that took the life of his passenger, police confirmed.
15-09-2021 · However, PFE stock has seen a decline of over 6% since then, and it is down 4% in the last five trading days. The recent decline can be attributed to rising concerns over the Biden administration ...
23 January 2021, Berlin: Pfizer's logo is displayed at one of its corporate offices. Since 2020, ... [ ] Pfizer has been working with the company Biontech on the development of a Covid 19 vaccine. Photo: Christophe Gateau/dpa (Photo by Christophe Gateau/picture alliance via Getty Images)dpa/picture alliance via Getty Images
[Updated: 9/16/2021] Pfizer Stock Decline
A few weeks back, we discussed that Pfizer’s (NYSE: PFE) stock price could rebound over a one-month period after falling 4% in a week, based on its historical performance. However, PFE stock has seen a decline of over 6% since then, and it is down 4% in the last five trading days. The recent decline can be attributed to rising concerns over the Biden administration’s plan to reduce healthcare costs, including negotiating the drug prices in its Medicare program. This has resulted in a sell-off in some of the large pharmaceutical stocks, including Pfizer, Merck, and Johnson & Johnson, among others.
In another recent development, the U.S. FDA stated that the booster shots of Pfizer’s Covid-19 vaccine might not be needed, even though it generates a higher immune response. The FDA’s stand stems from the fact that it is yet to be proven that the efficacy of Pfizer’s vaccine is declining. The vaccine has been found to be effective against Covid-19 so far, and a booster shot will make sense only after there are signs of declining efficacy.  But will PFE stock continue its downward trajectory over the coming weeks, or is a recovery in the stock imminent?
As we discussed in our previous update, according to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for PFE stock average around 3% in the next one-month (twenty-one trading days) period after experiencing a 4% drop over the previous week (five trading days). Our dashboard on Pfizer stock chance of a rise offers more details.
So, going by historical performance, it is likely that PFE stock will see a rebound going forward. But if there were serious in-roads to the development around the government’s plans to negotiate drug costs, it may result in bearish sentiment for pharmaceutical companies at large. That said, it is likely that the overall process may take a long time to materialize - if it does. Back in 2018, the Trump administration also created a blueprint to lower drug prices, but it didn’t actually materialize. There are several factors that need to be addressed while trying to control drug prices - the most relevant one being that long-term patient access to drugs will be significantly impacted, given that price control will directly result in fewer new drugs being developed.
We believe that long-term investors are likely to be better off buying the recent dip in PFE stock, based on both - the historical performance of the stock, as well as going by our Pfizer Valuation of per share based on .65 adjusted EPS and a P/E multiple of 11x for the full-year 2021.
[Updated: 8/25/2021] PFE Stock Decline
The stock price of Pfizer (NYSE: PFE) reached an all-time high of last week before a recent sell-off in Covid-19 vaccine stocks drove PFE down to its current level of around . PFE stock has fallen 4% over the last five days. The decline was seen in other Covid-19 vaccine stocks as well, including Moderna and Novavax. There is no announcement or development that should warrant any concern. The decline appears to be profit-booking at the higher levels. PFE stock has moved over 30% year-to-date. The figure is actually big for a large-cap pharmaceutical company. For perspective, Merck moved barely 1% while other large pharmaceutical stocks, such as Johnson & Johnson, Roche, and Bristol Myers Squibb, have moved around 12% each. But will PFE stock continue its downward trajectory over the coming weeks, or is a recovery in the stock imminent?
According to the Trefis Machine Learning Engine, which identifies trends in the company’s stock price using ten years of historical data, returns for PFE stock average around 3% in the next one-month (twenty-one trading days) period after experiencing a 4% drop over the previous week (five trading days).
Furthermore, Pfizer’s Covid-19 vaccine has received full U.S. FDA approval earlier this week. While the shot is being distributed on an emergency use basis currently, a full authorization may encourage more people who were previously on the fence about getting vaccinated to finally take the shot. Moreover, having a fully approved vaccine could possibly enable businesses to require mandatory vaccinations. This could lead to incrementally higher demand for Pfizer’s vaccine. Our Pfizer vaccine updates have more details. We believe that PFE stock will likely rebound after its recent fall and continue to make fresh highs in the near term.
But how would the returns fare if you are interested in holding Pfizer stock for a shorter or a longer time period? You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Pfizer stock chance of a rise after a fall. You can test the chance of recovery over different time intervals of a quarter, month, or even just 1 day!
MACHINE LEARNING ENGINE – try it yourself:
IF PFE stock moved by -5% over five trading days, THEN over the next twenty-one trading days PFE stock moves an average of 3%, with a 62% probability of a positive return over this period.
Some Fun Scenarios, FAQs & Making Sense of Pfizer Stock Movements:
Question 1: Is the average return for Pfizer stock higher after a drop?
Answer: Consider two situations,
Case 1: Pfizer stock drops by -5% or more in a week
Case 2: Pfizer stock rises by 5% or more in a week
Is the average return for Pfizer stock higher over the subsequent month after Case 1 or Case 2?
PFE stock fares better after Case 1, with an average return of 2.7% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 1.5% for Case 2.
In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise.
Try the Trefis machine learning engine above to see for yourself how Pfizer stock is likely to behave after any specific gain or loss over a period.
Question 2: Does patience pay?
Answer: If you buy and hold Pfizer stock, the expectation is over time the near-term fluctuations will cancel out, and the long-term positive trend will favor you - at least if the company is otherwise strong.
Overall, according to data and Trefis machine learning engine’s calculations, patience absolutely pays for most stocks!
For PFE stock, the returns over the next N days after a -5% change over the last five trading days is detailed in the table below, along with the returns for the S&P500:
You can try the engine to see what this table looks like for Pfizer after a larger loss over the last week, month, or quarter.
Question 3: What about the average return after a rise if you wait for a while?
Answer: The average return after a rise is understandably lower than after a fall as detailed in the previous question. Interestingly, though, if a stock has gained over the last few days, you would do better to avoid short-term bets for most stocks.
It’s pretty powerful to test the trend for yourself for Pfizer stock by changing the inputs in the charts above.
[Updated: 8/3/2021] PFE Stock Update
The stock price of Pfizer (NYSE: PFE) has seen an 11% rise over the last twenty-one trading days, and most of the gains have come over the last ten trading days, after the company reported strong Q2 results, and revised its full-year outlook upward. Note that such a move for PFE stock is uncommon, and it has occurred less than 60 times over the last 10 years. Pfizer continues to see strong sales from its Covid-19 vaccine, which remains the key growth driver. The vaccine garnered .8 billion in sales during Q2 2021, and it will likely add another billion to the company’s top-line over the next two quarters, in our view.
However, now that PFE stock has seen a rise of 11% in twenty-one trading days, will it continue its upward trajectory, or is a fall imminent? Going by historical performance, there is almost an equal chance of a rise or a fall in PFE stock over the next month. Out of 58 instances in the last ten years that PFE stock saw a twenty-one day rise of 11% or more, 30 of them resulted in PFE stock rising over the subsequent one month period (twenty-one trading days). This historical pattern reflects 30 out of 58, or about 52% chance of a rise in PFE stock over the coming month. See our analysis on Pfizer Stock Chance of A Rise for more details. While the 52% chance means the stock could go in either direction, Trefis estimates Pfizer’s Valuation to be around per share, which is nearly 14% above the current market price of around , implying that there is more room for growth in PFE stock.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
- After moving 5.1% or more over a five-day period, the stock rose in the next five days only on 49% of the occasions.
- After moving 9.5% or more over a ten-day period, the stock rose in the next ten days on 57% of the occasions
- After moving 11.0% or more over a twenty-one-day period, the stock rose in the next twenty-one days on 52% of the occasions.
Predict average return on Pfizer Stock Return: AI Predicts PFE Average and Excess Return After a Fall or Rise
Pfizer Stock Return (Recent) Comparison With Peers
- Five-Day Return: PFE highest at 5.1%; MRK lowest at -1.4%
- Ten-Day Return: PFE highest at 9.5%; MRK lowest at -1.1%
- Twenty-One Days Return: PFE highest at 11%; MRK lowest at -2.3%
[Updated: 7/28/2021] Pfizer Earnings Update
Pfizer (NYSE: PFE) today reported its Q2 results, which were below our expectations but beat the consensus estimates. The company reported revenues of .0 billion, lower than our forecast of .7 billion, and above the .5 billion consensus estimate. Our forecast was driven by higher contribution of Pfizer’s Covid-19 vaccine, which came in at .8 billion. Looking at the bottom line, the company reported adjusted EPS of
We have forecast the Covid-19 vaccine sales to be nearly billion in 2021, compared to billion per Pfizer’s earlier guidance. However, the company has now revised this guidance upward to .5 billion. So far, the company has recorded sales of .3 billion from its Covid-19 vaccine, implying another .2 billion expected over the next two quarters. Overall, it appears that the Covid-19 vaccine continues to drive the company’s top and bottom line expansion for now, but leaving that aside, revenue grew 10%, led by strong growth in biosimilars and alliance revenues. We will update our model to reflect the recently announced numbers. The street is likely to take these numbers on a positive note, given that Pfizer has also revised its full-year earnings outlook upward. Trefis estimates Pfizer’s Valuation to be around per share, which is nearly 20% above the current market price of around .
[Updated: 7/26/2021] Pfizer Q2 Earnings Preview
Pfizer (NYSE: PFE) is scheduled to report its Q2 2021 results on Wednesday, July 28. We expect the company to likely post revenue and earnings well above the consensus estimates, primarily led by its Covid-19 vaccine. Pfizer should see an overall pickup in pharmaceutical demand due to an increase in hospital visits with economies opening up gradually. We expect the company to navigate well based on these trends over the latest quarter.
Furthermore, we also think PFE stock remains attractive at the current valuation. Trefis’ forecast indicates that Pfizer’s valuation is per share, which is 19% above the current market price of . Our interactive dashboard analysis of Pfizer’s Pre-Earnings has additional details.
(1) Revenues expected to be above the consensus estimates
Trefis estimates Pfizer’s Q2 2021 revenues to be around .7 billion, 17% above the .5 billion consensus estimate. Now that the economies are opening up with vaccination programs underway in multiple countries, pharmaceutical companies will likely benefit from an increase in the volume of new patient starts. For Pfizer, its Covid-19 vaccine remains the key growth driver in the near term, with 2021 annual sales projected to be as high as billion, per Trefis estimates. Pfizer’s Q1 2021 sales were up 42% y-o-y to .6 billion, primarily driven by .5 billion sales from its Covid-19 vaccine, and the contribution of this vaccine is expected to be much higher in Q2. Our dashboard on Pfizer Revenues offers more details on the company’s segments.
2) EPS likely to be also above the consensus estimates
Pfizer’s Q2 2021 adjusted earnings per share is expected to be
(3) Stock price estimate 19% above the current market price
Going by our Pfizer’s Valuation, with an EPS estimate of .75 and a P/E multiple of 10x in 2021, this translates into a price of , over 19% higher than the current market price of . While the 10x figure is lower than the levels of over 14x seen in 2018 and 16x as recently as late 2020, this can be attributed to the fact that Pfizer’s EPS will be very high in 2021, followed by a decline from 2022 onward, with a slowdown in Covid-19 vaccine sales. Look at our Pfizer Covid-19 Vaccine Updates for more details.
Note: P/E Multiples are based on Share Price at the end of the year and reported (or expected) Adjusted Earnings for the full year.
While PFE stock looks attractive at its current levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Mettler vs Abbott.Invest with Trefis Market-Beating Portfolios
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
Why has Pfizer stock floundered?Pfizer chief corporate affairs chief Sally Sussman shares lessons from how the company responded to the global pandemic. INC. TODAY'S MUST READS: New Research: Status Reports Can Make Teams Less Effective INC. TODAY'S MUST READS: How to Stay Innovative ...Pfizer CEO Urges Biden to Form Coalition to Lower Drug Costs
Should I buy Pfizer Inc. (PFE)?Pfizer Inc. (NYSE:PFE) released its full-year results, but the market seems to be already pricing-in a decline. Shares are down 4.4% to US.5 in the past week, and the stock is currently in the red. Markets are forward-looking, and the price decline ...Pfizer expects a record 0 billion in revenue this year, thanks to COVI…
Why did Pfizer acquire Hospira?Pfizer and Hospira have entered into a definitive merger agreement under which Pfizer will acquire Hospira, a leading provider of injectable drugs and infusion technologies and a global leader in biosimilars, for approximately USbn. The Boards of Directors of both companies have unanimously approved the merger. 'Hospira’s business aligns well with our new commercial structure and is an excellent strategic fit for our Global Established Pharmaceutical (GEP) business, which will benefit ...Pfizer to Acquire Hospira
Where will Pfizer be in 5 years?Pfizer’s early data showed two of the extra-low doses were safe for kids under 5 and strong enough to give good protection to babies as young as 6 months. But once tots reached the preschool age -- the 2- to 4-year-olds -- two shots didn’t rev up ...Pfizer’s COVID-19 vaccine for kids under 5 will be delayed
Dowd predicts Moderna will drop to zero with bankruptcy as fraud related to concealing the COVID vaccine dangers surfaces, and he predicts Pfizer will become a sub-ten-dollar stock. Dowd explains that the smart money has …
Wall Street investors are dumping their Moderna and Pfizer stock faster than the world can drop the mandates. Moderna is down 70 percent from its high, while Pfizer is off 19 percent. Former Blackrock Executive and investment adviser Edward Dowd calls for Moderna to go to zero and Pfizer to end under ten dollars per share.
How is this possible given that Pfizer now enjoys record earnings per share and a market capitalization of some 0 billion, making it the 29th largest corporation globally? With nothing but profits in sight for the Pharmaceutical giant, what could be the problem?
After all, in December, a Forbes' headline read, "The Vaccine Maker Can Dominate The Covid Market For Years to Come, Wells Fargo Predicts." In addition to the enormously profitable mRNA vaccines, Pfizer is rolling out potent antivirals like Paxlovid, which could earn billion in 2022.
Compared to the billion in 2021 revenue, the earnings from the vaccines and the antivirals could top 2 billion for 2022, which is music to shareholders' ears. However some are hearing shrieks, and these happen to be Wall Street's finest, the smart money that beats the rest of the herd to the exits like clockwork.
These sophisticated investors make it their business to not go with the conventional wisdom but to do their own research, which often pays spectacular dividends.
Edward Dowd is one such investor. He saw the dot com bubble ready to burst and acted accordingly. But, unfortunately, other not-so-savvy investors later saw their dot com heavy portfolios collapse as the NASDAQ Composite Index lost 40% of its value in 2000.
Dowd, a graduate of Notre Dame University and former Portfolio Manager at Blackrock, grew his fund from billion to billion and commanded the respect of his investment community peers.
Today, after semi-retiring to the shores of South Maui, he remains a voice of stock market wisdom that many hedge funds continue to rely upon. LinkedIn lists him as a Consultant to Founder & Partner of Symphonic Capital, LLC.
But the dot com collapse is not the only one Dowd successfully navigated. While many other portfolio managers placed their client's money in highly rated and lucrative mortgage-backed securities, Dowd hesitated and questioned. He considered that those might be grossly over-rated, and he was correct.
It turns out that the mortgage rating system was corrupted by the high profitability of predatory financial products tied to home mortgages. According to Edward Dowd, a large portion of the blame was shouldered by the rating agencies, those trusted organizations whose job it was to judge the risk of these subprime mortgage-backed securities – agencies like Moody’s, Standard & Poor’s and Fitch.
Dowd says they turned a blind eye to the true risk because it was profitable. So, in essence, these rating agencies were captured by the institutions backing these risky subprime securities.
Joseph Stiglitz, a Nobel Prize-winning economist, put it this way, "The incentive structure of the ratings agencies also proved perverse. Agencies such as Moody's and Standard & Poor's are paid by the very people they are supposed to grade. As a result, they've had every reason to give companies high ratings, in a financial version of what college professors know as grade inflation."
Dowd has sounded the alarm on Moderna and Pfizer as sinking ships that investors need to abandon. So what does the man who foresaw the dot com and the subprime mortgage crisis have to say about Moderna and Pfizer, and what trouble could exist in the paradise of COVID vaccine profits?
Here are Dowd’s words:
I want to liken here to what's gone on in the Great Financial Crisis. We had rating agencies, third-party verification sources that were able to perpetuate the fraud because the money got too big, their institutions became corrupted with the institutional imperative, and they got triple-A ratings which we all know in hindsight were not triple-A ratings – let's move forward to today.
The FDA is the trusted third-party verification of pharmaceutical products. 50% of their budget comes from Pharma...due to the institutional imperative that was in place at the time and the speed with which they tried to approve these unproven products with this unproven technology, fraud did occur, and what's my proof of that? The FDA, together with Pfizer, were trying to hide the clinical data.
And it’s come out recently...that the all-cause mortality for the Pfizer product failed – that means there were more deaths in the vaccine group than the placebo group. Normally in such a case, you have NO drug approval for such drugs. It's the gold standard. I've been told by all my people in the Biotech Industry they were horrified... See mark 25:10.
And unfortunately, that is not all. Dowd feels that although he has successfully predicted three large frauds in his career, he now expects a global financial market collapse with the debt bubble getting ready to burst.
“So I’ve seen three frauds; the corporate fraud of the dot com boom, the bank fraud of the Great Financial Recession, and I believe the fraud has moved on to central banks and governments – because that’s the nature of our monetary system – you have to constantly create credit to keep this thing going.” See mark 2:22.
“The global debt bubble is at its peak…we are at the end…we are going to see lots of crazy things in the financial markets…we are going to see the credit markets become unhinged, the equity markets become unhinged. The Fed got a reprieve…under the cover of COVID, they were able to print 65% more money to keep this thing afloat, but we are at the end days here.” See mark 3:41.
He clarifies that the emergence of global totalitarianism is not purely about power and profit. Instead Dowd feels it is to control the masses when they realize the economy is collapsing – the ramifications of which may be the loss of pensions and social security income.
“A lot of what you are seeing in the response of global governments is setting up a system – under the guise of medical tyranny – to prevent the riots that are going to ensue once this thing all unwinds – that’s my personal belief…” See mark 4:04.
For the skeptics, consider that Pfizer stock lost billion in market capitalization on February 8, 2022, when their record earnings fell short of more optimistic expectations.
Also consider that Moderna's stock is down some 70 percent from its high of 4 on August 9, 2021, wiping out almost $ 140 billion in investment.
Dowd predicts Moderna will drop to zero with bankruptcy as fraud related to concealing the COVID vaccine dangers surfaces, and he predicts Pfizer will become a sub-ten-dollar stock. Dowd explains that the smart money has already left Moderna and will soon be exiting Pfizer.
Dowd foresees an avalanche of lawsuits coming as the insurance industry continues to uncover the legions of mounting deaths coming from the complications of the mRNA COVID-19 vaccines.
Dowd teamed up with an insurance industry analyst and researched the life insurance claims. They found that since OneAmerica shocked the world by announcing a 40% rise in non-COVID deaths in younger working-class employees, multiple other insurance companies worldwide have seen the same thing – massive rises in non-COVID deaths. And the evidence inescapably points to the vaccines as the cause. See mark 13:16.
Meanwhile, the funeral company stocks have outperformed the S&P. “Funeral Home companies are growth stocks. They had a great year in 2021 compared to 2020, and they outperformed the S&P 500. The peer group of Funeral Home stocks was up 40 plus percent while the S&P was up 26 percent – and they started accelerating price-wise in 2021 during the roll-out of the vaccines – You don’t need to be a rocket scientist to connect the dots here.” See mark 5:55.
Other insurance companies have reported the same or worse death numbers as OneAmerica. For example, “Unum Insurance is up 36%, Lincoln National plus 57%, Prudential plus 41%, Reinsurance Group of America plus 21%, Hartford plus 32%, Met Life plus 24%, and Aegon – which is a Dutch insurer – saw in their US arm plus 57% in the 4th quarter – in the 3rd quarter they saw a 258% increase in death claims.” See mark 07:55.
“They raised (mortality) expectations 300,000 for 2022 over 2021 due to COVID plus 'indirect COVID,' which I think we know what that’s code for... They (Aegon) did a
"Someone is going to be the bag holder here." And Dowd is confident it won't be the insurance industry. A court in France has already held that a life insurance company cannot be held liable for a death because of the mRNA vaccine.
But that does not explain how mRNA manufacturers can be held responsible for an emergency product they were told was liability-free. Aren't the vaccine manufacturers immunized from lawsuits?
After all, they were granted EUA, the specialized Emergency Use Authorization, which means they cannot be held legally accountable for deaths or adverse effects stemming from the experimental vaccines.
The idea is that no company – upon government request – should have to pay for unforeseen complications resulting from an emergency product that they released to the world out of their goodness of the hearts, with the best of intentions. Right?
Wrong – not when your company accomplishes this through deceit, also known as fraud.
Fraud undoes all these protections. If a company or person intentionally deceives another to profit, we have fraud. If Pfizer’s data showed increased all-cause mortality and hid this to motivate people to take the vaccine while claiming it was safe, then fraud exists.
Under common law, the required elements to prove fraud amount to:
#1. A materially false statement or purposeful failure to state or release material facts which non-disclosure makes other statements misleading.
#2. The false statement is made to induce Plaintiff to act.
#3. The Plaintiff relied upon the false statement, and the injury resulted from this reliance.
#4. Damages include a punitive award as a punishment that serves as a public example to discourage any future similar fraud. Punitive damages are generally proportional to the Defendant's assets.
Dowd has been researching the COVID-19 vaccines and what he considers obvious evidence of knowing concealment of the actual risks of death – and he points to the Herculean efforts of Pfizer with FDA in withholding their data despite legal challenges to release it. He likens the FDA today to the rating agencies during the Mortgage Crisis.
"FDA is the trusted third party, just like the rating agencies were. And a lot of doctors in this country, a lot of local governments are placing their trust in the FDA which gets 50 percent of its budget from large cap pharma. It wasn't any one person...I think they overlooked things...An all-cause mortality end-point should have stopped this thing in its tracks – and it didn't." See mark 1:51.
There were more deaths in the vaxxed group than in the unvaxxed. Dowd assumes fraud based upon the FDA backing Pfizer in not releasing their data. He believes this is a knowing attempt to conceal the deaths.
“When one party enters into a contract…and fraud was occurring when they entered into that contract, and the other party did not know that – the contract is void and null. There’s no indemnity if this can be proven, and I think it will be.” See mark 4:45.
"Pfizer got blanket immunity with EUA. If fraud occurred, to my mind and what I'm seeing from their refusal to release the data – if there is fraud and it comes out – and we need whistleblowers – and it's looking more apparent that this product is deadly –
fraud eviscerates all contracts – that's case law. So you go down the daisy chain, and that’s liability – that's bankruptcy for Moderna, definitely Pfizer." See mark 00:51.
Dowd remarks that no matter the effort, one cannot hide the bodies – and “the bodies are piling up.” See mark 12:56.
He notes that the deaths skyrocketed after the vaccine rollout when they should have dropped. And the deaths are what distinguished the 2021-2022 vaccine scandal as far worse than what happened with Enron.
"People are dying and being maimed. This is a fraud that goes beyond the pale...We have the VAERS data...We have the DoD leak...And now we have the insurance company results and the funeral home results...We don't need to think too hard about this...Deaths should have gone down after the vaccines rolled out. This is the most egregious fraud in history of the nation – and it's global...Pfizer's involved, and they committed fraud," Dowd explained. See mark 10:25.
"My job is to be ahead of the news and be a lead steer...when I use my stock picking skills outside the realm of stock picking, I am called a conspiracy theorist." See mark 6:45.
Dowd emphasized that he is not short on Pfizer or Moderna stock. He explained that he does not profit from their share prices dropping. He also points out that his predictions are not the cause of the steep declines as these occurred before he came out with this analysis. See mark 13:45.
"Let me make a point here. The mainstream media may ignore this. Wall Street is not." See mark 2:16.
"This is the most interesting hallucination I've ever seen in the financial markets." See mark 12:06.
"So we don't need the mainstream media...And I want you to know – Wall Street is rallying to this – I'm getting lots of inquiries from former colleagues. Nothing will convince a sleeping public more than red stocks or collapsing stocks. My goal is to awaken the country by seeing something is going on. And Wall Street is AWAKE!" See mark 2:33.
If money is any indicator, Edward Dowd is correct that insurance will win a fight between the insurance and the vaccine industries. The life insurance market in the US is worth some 0 billion, while the vaccine market pales in comparison.
If someone is left holding the bag, it will not be the insurance industry, but it just might be you and me, the average citizen. However, there is one major caveat – if Edward Dowd succeeds in awakening the citizens, then they – the oligarchs – cannot get away with this – the Vaccine Fraud, the Great Reset, the Fourth Industrial Revolution and Global Totalitarianism.
"There's lots of people who got the jabs that didn't understand what was going on. A lot of them are in the investment world. A lot of them are smart people – they were duped too. Some of these people that got the jab are doing the work on shorting these stocks because – you know, you can guess – because they are mad as hell – and you've awakened the sleeping giant known as Wall Street. And Wall Street is on the move. The smart money is moving first – as always there's lead steers. Nothing gets going faster than a red momentum down-trending stock.” See mark 3:26.
Those of you who still think nothing's going on, you don't want to be – what I call – the bag holder. You don't want to be the guy taking the fourth jab booster and holding these stocks (on their way) down – Moderna's going to zero – I think Pfizer goes sub ten dollars once the lawsuits come out. " See mark 4:06.
Dowd’s forecast can awaken not only Wall Street but the ordinary citizen. We are those sleeping giants of the world, those who can move mountains with the force of our stock sales and non-violent protests, the great silent majority who can remove dictators from power and elect new and fair leaders.
There is power in numbers, as the Canadian Truckers recently found. Courage is contagious as freedom convoys have sprung up everywhere. We hold the power if we choose to exercise it while we lose that power if we passively comply.
As this Freedom Trucker fireman said, "I don't know what happened to our country. It's disgusting. There's nothing that's going to be taken from us here today that they're not going to take anyways – And people need to stand. With enough of us, they can't do this." See mark 1:58:10.
If enough of us speak out NOW, collectively, we have the power to not only end the mandates, but to restore ALL freedoms in Canada, Australia, the UK, Europe and the United States, and we will win the day. We will never consent to authoritarian rule.
We will not leave a world of slavery to our children and grandchildren. We will protest every single day until the government realizes who truly is in charge. We believe in government of the people, by the people, and for the people. The cure for 1984 remains 1776.
Edward Dowd cautions those who continue to slumber, “If you are long these two stocks, you are long mandates, you are long government control, and you are long the selling of your freedoms.” Let us get everyone on board the freedom train. See mark 15:16.
With enough of us (awake), they can’t do this. Americans and Canadians are united in Freedom!
Pfizer Ltd., incorporated in the year 1950, is a Large Cap company (having a market cap of Rs 23,476.59 Crore) operating in Pharmaceuticals sector. Pfizer Ltd. key Products/Revenue Segments include Pharmaceuticals, Sale of services and Scrap for the year ending 31-Mar-2021.
Quarterly | Annual Sep 2021 Jun 2021 Mar 2021 Dec 2020 Sep 2020 Total Income 651.29 761.41 571.96 608.06 607.56 Total Income Growth (%) -14.46 33.12 -5.94 0.08 14.18 Total Expenses 474.12 490.43 436.33 423.95 419.82 Total Expenses Growth (%) -3.33 12.40 2.92 0.98 18.01 EBIT 177.17 270.98 135.63 184.11 187.74 EBIT Growth (%) -34.62 99.79 -26.33 -1.93 6.46 Profit after Tax (PAT) 142.95 199.91 100.55 141.24 131.37 PAT Growth (%) -28.49 98.82 -28.81 7.51 5.56 EBIT Margin (%) 27.20 35.59 23.71 30.28 30.90 Net Profit Margin (%) 21.95 26.26 17.58 23.23 21.62 Basic EPS (₹) 31.25 43.69 21.98 30.87 28.71 Quarterly | Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 Total Revenue 2,319.67 2,335.67 2,248.89 2,082.80 2,067.42 Total Revenue Growth (%) -0.69 3.86 7.97 0.74 -1.52 Total Expenses 1,650.95 1,693.18 1,588.98 1,534.89 1,681.02 Total Expenses Growth (%) -2.49 6.56 3.52 -8.69 2.58 Profit after Tax (PAT) 497.61 509.13 429.05 360.07 336.78 PAT Growth (%) -2.26 18.66 19.16 6.92 10.43 Operating Profit Margin (%) 30.54 30.36 31.76 27.85 19.70 Net Profit Margin (%) 22.22 23.66 20.61 18.29 17.12 Basic EPS (₹) 108.77 111.28 93.78 78.70 73.61
All figures in Rs Cr, unless mentioned otherwise
No reported Profit & Loss Statement are available.
Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 Total Assets 3,265.90 4,405.40 3,939.99 3,689.96 3,260.96 Total Assets Growth (%) -25.87 11.81 6.78 13.16 12.91 Total Liabilities 872.86 1,009.91 928.65 1,006.76 842.08 Total Liabilities Growth (%) -13.57 8.75 -7.76 19.56 16.22 Total Equity 2,393.04 3,395.49 3,011.34 2,683.20 2,418.88 Total Equity Growth (%) -29.52 12.76 12.23 10.93 11.80 Current Ratio (x) 2.49 3.49 3.05 2.53 2.63 Total Debt to Equity (x) 0.00 0.00 0.00 0.00 0.00 Contingent Liabilities 254.98 254.60 219.12 471.89 498.58
All figures in Rs Cr, unless mentioned otherwise
Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 Net Cash flow from Operating Activities 427.33 323.18 97.81 331.80 328.82 Net Cash used in Investing Activities -468.84 1,530.32 35.12 -238.30 -249.64 Net Cash flow from Financing Activities -1,571.07 -163.52 -109.85 -110.35 -82.59 Net Cash Flow -1,612.58 1,689.98 23.08 -16.85 -3.46 Closing Cash & Cash Equivalent 151.21 1,763.79 73.81 50.73 67.59 Closing Cash & Cash Equivalent Growth (%) -91.43 2,289.64 45.50 -24.94 -4.87 Total Debt/ CFO (x) 0.01 0.01 0.03 0.01 0.01
All figures in Rs Cr, unless mentioned otherwise
Annual FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 Return on Equity (%) 20.79 14.99 14.24 13.41 13.92 Return on Capital Employed (%) 27.44 18.49 21.69 20.04 15.61 Return on Assets (%) 15.23 11.55 10.88 9.75 10.32 Interest Coverage Ratio (x) 45.26 60.22 512.56 1,305.55 403.50 Asset Turnover Ratio (x) 68.54 48.84 52.83 53.34 60.29 Price to Earnings (x) 41.67 36.23 35.46 27.78 25.77 Price to Book (x) 8.64 5.42 5.04 3.73 3.58 EV/EBITDA (x) 24.67 21.41 18.13 13.39 15.85 EBITDA Margin (%) 35.43 35.16 35.19 31.22 22.90
But the stock has since retreated, providing a total return of 6.0% over the past 12 months, below the S&P 500's total return of 13.5%. Source: TradingView. …
- Adjusted EPS missed analyst forecasts.
- Revenue beat analyst expectations.
- Pfizer reported first sales figures for COVID-19 vaccine.
Pfizer reported Q4 FY 2020 adjusted EPS that missed analyst expectations. Revenue, however, surpassed analyst forecasts. Pfizer said that its COVID-19 vaccine, co-developed with BioNTech, contributed 4 million in revenue during the quarter.
The company modified its figures to exclude financial contributions from its off-patent and generic-drug unit Upjohn, which was spun-off in November. Thus, Pfizer's reported revenue and adjusted EPS figures are not comparable to the figures reported in the story below.
(Below is Investopedia's original earnings preview, published February 1, 2021.)
Pfizer Inc. (PFE), one of the world's largest drug companies, has recruited Sanofi S.A. (SNY) to help it speed up the production of its COVID-19 vaccine. The goal is to produce millions of new doses of the vaccine, co-developed by Pfizer and BioNTech S.E. (BNTX), to meet soaring demand. Despite major setbacks including supply chain obstacles, longterm high demand for the vaccine could bolster Pfizer's lackluster profits.
Investors will be focused on whether Pfizer has been able to slow the trend of declining earnings and revenue that began last year when the company reports earnings on February 2, 2021 for Q4 FY 2020. Investors are likely to be disappointed. Analysts expect adjusted earnings per share (EPS) and revenue to fall compared to the year-ago quarter.
One reason for Pfizer's weaker financial performance this year is due to shelter-in-place measures related to the COVID-19 pandemic that have slowed demand for new prescriptions and vaccinations. Another reason is due to the loss of revenue from its consumer-health business, which was spun off to GlaxoSmithKline PLC (GSK) in a joint venture in mid-2019. The move was part of a broader restructuring that Pfizer is undergoing to focus on developing new drugs with a bigger potential for sales growth. Also part of the restructuring was Pfizer's spin-off of its off-patent and generic-drug unit Upjohn in November of last year. Upjohn combined with Mylan N.V. to form a new company named Viatris Inc. (VTRS).
Shares of Pfizer have underperformed the broader market over the past year. They had begun to outperform after a sharp rebound from the pandemic-induced market crash that occurred between late February and late March 2020. While that outperformance was short lived, the stock did receive a boost in early November when Pfizer reported its COVID-19 vaccine had an efficacy rate of more than 90%, and jumped again when the company applied for emergency use of its vaccine in the second half of November. But the stock has since retreated, providing a total return of 6.0% over the past 12 months, below the S&P 500's total return of 13.5%.
The stock tumbled after Pfizer reported earnings for Q3 FY 2020. Adjusted EPS fell 3.2%, marking the fifth consecutive quarter of year-over-year (YOY) declines. Revenue fell 4.3%, the sixth consecutive quarter of declines. Pfizer estimated that the pandemic had an unfavorable impact on revenue of around 0 million. But despite falling revenue and adjusted EPS, CEO Dr. Albert Bourla expressed confidence in the company's ability to generate longterm growth as a smaller, more focused drug company.
The second quarter marked a recent low for Pfizer's revenue, which fell 11.0% compared to the same three-month period a year ago. It was the largest decline in revenue in at least 12 quarters. Adjusted EPS dipped 1.7% compared to the year-ago quarter. Similar to Q3, Pfizer noted that the fallout from the pandemic led to an adverse impact on sales of around 0 million, or 4% of total revenue.
Analysts are forecasting adjusted EPS and revenue to fall 3.1% and 4.1%, respectively, in Q4 FY 2020. That would mark the sixth consecutive YOY decline in earnings and the seventh consecutive decline in revenue.
For full-year FY 2020, analysts expect adjusted EPS to fall 7.3%, the first annual decline in at least four years. Revenue is expected to fall 10.5%, the sharpest drop in at least four years. Given these declines, Pfizer will depend heavily on robust sales of its COVID-19 vaccine to engineer a turnaround in its earnings performance.
|Pfizer Key Metrics|
|Estimate for Q4 2020 (FY)||Q4 2019 (FY)||Q4 2018 (FY)|
|Adjusted Earnings Per Share ($)||0.53||0.55||0.63|
Source: Visible Alpha
03-12-2020 · Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.
Pfizer shares fell Thursday after a report said the U.S. drugmaker expects to ship half of the Covid-19 vaccines it originally planned for this year due to supply-chain problems.
The Wall Street Journal, citing a person directly involved in the development, said some early batches of the raw materials needed for the vaccine failed to meet standards. Pfizer now plans to ship 50 million vaccines by the end of the year, down from the original 100 million it had hoped to send out, according to the Journal.
"There are several factors which have impacted the number of doses estimated to be available in 2020," Pfizer said in a statement. "For one, scaling up a vaccine at this pace is unprecedented, and we have made significant progress as we have moved forward in the unknown."
The company has repeatedly said publicly that it planned to ship 50 million vaccine doses this year and up to 1.3 billion doses by the end of 2021. Still, Pfizer shares fell more than 2% in intraday trading Thursday before closing down more than 1% after the report published. In extended trading, the stock, which has a market value of 3 billion, was down less than 1%.
The report also caused sparked a late-day sell-off in the broader market.
Pfizer said Thursday, the scale up of the raw material supply chain took longer than expected. It also was delayed by the efforts it was making to produce vaccines for clinical trials. The company said its full scale production lines in the U.S. and Europe are now complete and it is "confident" it will be able to supply the targeted doses.
Vaccines can contain preservatives to prevent contamination, sterile water, genetic material of the virus and other ingredients, according to the Centers for Disease Control and Prevention.
Pfizer, which has been working alongside German drugmaker BioNTech, applied for an emergency use authorization from the Food and Drug Administration for their coronavirus vaccine on Nov. 20. Its vaccine uses messenger RNA, or mRNA, technology. It's a new approach to vaccines that uses genetic material to provoke an immune response.
Pfizer's vaccine requires a storage temperature of minus 94 degrees Fahrenheit. By comparison, Moderna has said its vaccine remains stable at 36 to 46 degrees Fahrenheit, the temperature of a standard home or medical refrigerator, for up to 30 days. It can be stored for up to six months at negative 4 degrees Fahrenheit.
The Federal Aviation Administration said it supported the "first mass air shipment" of vaccines last week. The company plans to ship frozen vials of the vaccine to vaccination points from its sites in Kalamazoo, Michigan, and Puurs, Belgium.
Pfizer announced on July 22 that the U.S. agreed to buy 100 million doses of its vaccine for up to
On Wednesday, the U.K. authorized Pfizer's vaccine, becoming the first country to do so.
Shares in Pfizer <PFE.N> fell on Monday after rival drugmaker Moderna <MRNA.O> said its experimental vaccine against COVID-19 was 94.5% effective and that it …
Scared of sky-high stock prices? These dirt-cheap stocks are good bets for 2022.
The billionaire investor expects the U.S. dollar to "slip pretty mightily."
A massive and surprising new transition could soon impact the wealth of thousands, while leaving everyone else worse off than before.
But the deals the U.S. aerospace giant lost to Airbus in December don't bode well for the company.
While many companies are scrambling to carve out their part of the metaverse, Nvidia is already marketing a successful product. Nvidia's graphics processing units (GPUs) should enjoy tremendous demand over the long term as well as the metaverse is built. Few companies can compete at the same level as Nvidia in powering virtual reality apps.
Last year we saw Emergency Use Authorizations for multiple COVID vaccines and treatments across the healthcare space. Pharmaceutical companies are set to make billions of dollars in 2022. Pfizer (NYSE: PFE), the 0 billion mega cap, is expected to bring in not
This is why investing in Plant Based Food Companies can make you a fortune in 2022 and the years to come..
Thanks to the dual headwinds of sky-high inflation and the threat of rising interest rates, biopharmaceutical stocks appear poised for a turbulent 2022. Underscoring this point, investors have been dumping risky clinical and early commercial-stage biopharma stocks over the past several weeks in response to these closely intertwined macro variables. This year thus seems destined to be a bona fide "stock-picker's market" for biopharma investors.
Whether at home, work, or play, software is likely to play a vital role in our activities. Due to annual recurring revenues (ARR), profitability, and high product demand, software companies make terrific investments. It is tough to talk about software stocks without mentioning the world's largest software company, Microsoft (NASDAQ: MSFT).
These solid companies are getting unfairly punished by the market. Savvy investors should take note.
2022 Mining Companies you definitely want on your radar this year with promising new developments.
Not only has the company produced an incredible 15.1% annualized return since its 1994 NYSE listing, it has also increased its dividend for 97 consecutive quarters and has made 617 consecutive monthly dividend payments (that's more than 51 years). If you aren't familiar, Realty Income is a real estate investment trust, or REIT, that invests in single-tenant properties.
The uber-wealthy investor is thrifty with everything from his breakfast to his house.
With the remote-work and virtual-learning trends accelerating during the pandemic, demand for Apple (NASDAQ: AAPL) products like the iPhone, Mac, AirPods, and iPads has surged. Apple's market value now stands at a stunning .8 trillion and recently topped trillion for a brief time. Here are two major catalysts that are likely to drive Apple's share price to new all-time highs in the coming year.
Washington drivers in these zip codes are surprised to find out they have been overpaying on their auto insurance bill.
Before Monday’s (Jan 10) trading truly kicks into action, Tilray (TLRY) will release its November (F2Q22) quarter results. Ahead of the print, Cantor’s Pablo Zuanic believes the trends are not tilting in the Canadian LP’s favor. “Unless the company issues bullish forward commentary, we expect the stock to face pressure from the November quarter print,” the analyst forewarned. While Zuanic notes that cannabis makes up less than half of the company’s sales (in the August quarter they accounted for
(Bloomberg) -- For those concerned that the decade-long super-easy monetary policy has created asset bubbles around the world, the first signs of trouble may be in the making for inflated markets.Most Read from BloombergCypriot Scientist Says Covid-19 Variant Deltacron Not an ErrorCyprus Finds Covid-19 Infections That Combine Delta and OmicronOmicron Study in South Africa Points to End of Acute Pandemic PhaseCrypto Diehards Are About to Find Out If It Really Was a BubbleVeteran Equity Strategist
One industry that is becoming increasingly important to our economy and will surely continue to breed some long-term investment winners is the semiconductor industry. The chip market is forecast to see sales rise by 8.8% to reach 1 billion in 2022, according to the Semiconductor Industry Association. The ongoing buildout of data centers and other high-performance applications is a big tailwind for leading component suppliers.
After discovering FORTY 1,000% winners, he just announced his favorite stock of the year. Get the name and ticker.
Higher oil and gas prices fueled some big-time gains across the sector last year. The improving market conditions have also bolstered the industry's financial picture, giving many energy companies the flexibility to pay higher dividends. Three energy dividend stocks that stand out as attractive buys this month are ConocoPhillips (NYSE: COP), Enbridge (NYSE: ENB), and Clearway Energy (NYSE: CWEN)(NYSE: CWEN.A). Higher oil prices have been a boon for ConocoPhillips.
This fast-growing player and well-rounded value stock deserve pole-position in a long-term EV portfolio.
If there is one takeaway from another muddled jobs report, it’s this, writes Lisa Beilfuss: The Federal Reserve is behind the curve and falling fast. Investors should brace for more aggressive tightening—and even welcome it.
Amazon Has Millions of Prime Subscribers — But Few Know About This Savings Trick
Here's why they chose AbbVie (NYSE: ABBV), Pfizer (NYSE: PFE), and Vertex Pharmaceuticals (NASDAQ: VRTX). Prosper Junior Bakiny (AbbVie): The bears have been predicting AbbVie's doom since the company lost patent protection for its blockbuster rheumatoid arthritis drug, Humira, back in 2018. While Humira's sales have been dropping like a rock in international markets, the drug continues to make headway in the U.S. During the third quarter, Humira's domestic sales grew by 10.1% year over year to .6 billion.
Valuation, sentiment on regulation, and big moves by a famous fund manager are helping the case for Alibaba stock. But there remains a case for caution.
Tesla's (NASDAQ: TSLA) record-high quarterly and full-year production and delivery numbers caught the market by surprise on Monday as its share price rose to within striking distance of its all-time high. Investors who follow the Chinese electric vehicle (EV) market might be interested to see how Tesla's numbers compare to those of Chinese EV heavyweight Nio (NYSE: NIO). Daniel Foelber (Tesla): According to reports by the China Passenger Car Association (CPCA), Tesla sold 54,391 China-made vehicles in October and 52,859 in November.
Moderna is the second U.S. company to report encouraging trial results on a COVID-19 vaccine, joining Pfizer (N: PFE) which has said its vaccine is also more than 90% effective.
By Danilo Masoni
MILAN (Reuters) - Shares in Pfizer (N:) fell on Monday after rival drugmaker Moderna (O:) said its experimental vaccine against COVID-19 was 94.5% effective and that it can be stored at normal fridge temperatures.
Moderna is the second U.S. company to report encouraging trial results on a COVID-19 vaccine, joining Pfizer (N:) which has said its vaccine is also more than 90% effective.
But while Pfizer's vaccine has to be stored and shipped at ultra-cool temperatures, Moderna said its product can be kept at normal fridge temperatures.
"This is very important, perhaps a game changer," said Fawad Razaqzada, analyst at ThinkMarkets.
"The Pfizer vaccine had to be kept in very cold temperatures of minus 70 degrees Celsius, making it logistically difficult to produce and transport large doses of the vaccine," he said.
Pfizer shares, which on Nov. 9 hit their highest levels since end July 2019, fell 4.1% by 1623 GMT, while shares in its German partner BioNTech were down 12.8%.
JPMorgan (NYSE:) analysts said the logistics of Moderna's vaccine were clearly less onerous although they expect storage requirements for both the vaccines to converge.
Moderna shares were up 9% after hitting a record high earlier on Monday, while shares in British drugmaker AstraZeneca (L:), which is yet to release results from its late-stage vaccine trials, were down 0.9%.
BEIJING (Reuters) - China's antimonopoly bureau will step up legal enforcement against monopolistic behaviour and push forward the amended antimonopoly law to improve the...
By Aditya Kalra NEW DELHI (Reuters) - Apple Inc (NASDAQ:AAPL) has asked India's antitrust watchdog to throw out a case alleging abuse of market power in the apps market, saying it...
By Maria Ponnezhath (Reuters) -CNN is closing its offices in the United States to all nonessential employees as COVID-19 cases increase, the network said on Saturday in an...
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
11-12-2020 · Pfizer stock dipped early Friday after the Food and Drug Administration said it would "rapidly" authorize the company's coronavirus vaccine.
Food and Drug Administration Commissioner Stephen Hahn said Friday the agency would "rapidly" authorize Pfizer (PFE) and BioNTech's (BNTX) coronavirus vaccine — but the move didn't seem to help Pfizer stock.X
Hahn's statement follows a positive vote Thursday from an FDA advisory committee. Panelists voted 17-4 to endorse the experimental coronavirus vaccine for individuals ages 16 and older. One panelist abstained from the vote.
"The U.S. Food and Drug Administration has informed the sponsor that it will rapidly work toward finalization and issuance of an emergency use authorization," Hahn said in a written statement. "The agency has also notified the U.S. Centers for Disease Control and Prevention and Operation Warp Speed, so they can execute their plans for timely vaccine distribution."
However, on today's stock market, Pfizer stock slipped 1.5% to 41.12. BioNTech stock fell 1.7% to 127.30. It's possible investors were looking for their coronavirus vaccine to gain emergency use authorization Friday.
Pfizer Stock: Vaccine Authorization Looms
The advisory committee meeting Thursday was an important step toward authorization of the coronavirus vaccine. Now, Pfizer says it expects the FDA to make a decision regarding issuing an emergency use authorization "in the coming days."
"We have been looking forward to presenting our robust data package to the committee of vaccine experts for the U.S. government since we began our efforts to develop a novel Covid-19 vaccine earlier this year," Pfizer Chief Executive Albert Bourla said in a written statement.
If authorized, Pfizer will work with the CDC and Operation Warp Speed to distribute its Covid-19 vaccine, Dr. Anita Patel said Thursday during the advisory committee meeting. Patel is a senior advisor for pandemic preparedness and response at the CDC.
Pfizer and BioNTech's coronavirus vaccine must be stored at ultra-cold temperatures. Further, the minimum shipping order is for 975 doses, Patel said. That leads to some challenges for rural communities. Pfizer's vaccine will head straight to distribution sites.
Other coronavirus vaccines will go through a distributor before heading out to administration sites, Patel said. That could include Moderna's (MRNA) coronavirus vaccine. The company is set to make its presentation before the advisory committee meeting next Thursday.
New Tech Behind Coronavirus Vaccine
Coronavirus vaccines from Pfizer and Moderna use never-before-approved technology. These drugs tell the body to make a structure that looks like the spike protein on the outside of the SARS-CoV-2 virus. As a result, the body preemptively mounts its immune system attack.
The immune response is similar to what the body would do when encountering the virus that causes Covid-19 in the wild, said Dr. Kathrin Jansen, Pfizer's senior vice president and head of vaccine research and development. Jansen presented Thursday in front of the committee.
"In a nutshell, the immune response induced by the (messenger RNA) vaccine is similar to what you might get in response to an infection," she said. "But, of course, the mRNA vaccine is noninfectious and cannot cause disease."
One benefit of this type of vaccine is that people can receive frequent booster shots, she said. This is key because experts still aren't sure how long immunity might last — either from viral infection or a coronavirus vaccine.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Wild Ride Continues For This Biotech Stock With A 998% Single-Day Gain
Pfizer, BioNTech Nab FDA Panel Recommendation For Covid Vaccine
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
Find Today's Best Growth Stocks To Watch With IBD 50
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
14-12-2021 · But Pfizer stock fell in late June after the CDC noted there's a link between the Pfizer/BioNTech and Moderna vaccines and the inflammation. The European Medicines Agency also warned against the ...
Pfizer stock yo-yoed in early December after researchers in South Africa identified a new Covid variant that undermines the effectiveness of its two-dose vaccine.X
The variant called omicron contains numerous mutations to the spike protein, which vaccines mimic to induce an immune response. In a test, Pfizer and its partner, BioNTech (BNTX), said the variant led to a significant reduction in virus-targeting antibodies. The booster dose, on the other hand, generated a substantial increase in antibodies.
Put another way, the booster dose resulted in a similar level of protection against omicron as the initial two-dose series does against the first iteration of the virus. Promisingly, the initial two-dose series may still protect against severe disease caused by omicron.
Further, the Food and Drug Administration and Centers for Disease Control and Prevention recently authorized Pfizer's Covid booster for all adults. Authorities also allowed a one-third sized dose of the original vaccine for children as young as 5.
On the treatment side, Pfizer also is working on a two-pill antiviral called Paxlovid that could treat mild-to-moderate Covid in unvaccinated patients. Paxlovid cut the risk of hospitalization or death by 89% when high-risk patients began taking it within three days of symptoms beginning. When people with a standard risk of severe disease took Paxlovid, it reduced hospitalization by 70%.
The results rival Merck's (MRK) antiviral pill. Merck's Ridgeback Biotherapeutics-partnered molnupiravir lowered the chance of hospitalization and death by 30% in a final analysis. Molnupiravir is a one-pill course that patients began taking within five days of symptoms beginning.
So, all in all, is PFE stock a buy?
Pfizer Stock Fundamentals: Earnings Strong
In the third quarter, adjusted Pfizer earnings were
The company's Covid vaccine brought in .98 billion in sales.
Revenue from blood thinner Eliquis, breast cancer drug Ibrance and pneumonia vaccine Prevnar all lagged forecasts, according to one analyst. Prevnar sales declined 6% to
Bearishly, sales of inflammatory drug Xeljanz slipped 7% to 0 million. The FDA recently said Pfizer and some of its competitors would have to add warnings to the labels for Xeljanz and other drugs in their class. Testing shows patients taking these medicines have a heightened risk of blood clots, heart-related events, cancer or death.
Meanwhile, Chantix sales crashed 97% to million after Pfizer recalled the medicine due to a higher-than-acceptable level of a possible cancer-causing substance.
Overall, total third-quarter growth lined up with CAN SLIM rules for investing. Investors are encouraged to seek stocks with 20%-25% recent sales and earnings growth. But excluding the impact of the Covid vaccine, sales grew just 7% operationally.
Big institutional investors — who account for up to 70% of all market trades — usually look for stocks with accelerating earnings and sales growth.
That trend is expected to continue in the fourth quarter. Analysts polled by FactSet call for adjusted income of 91 cents a share and .34 billion in sales, up a respective 117% and 108%.
Pharmaceutical Company's Annual Metrics
Pfizer's sales popped 2% last year to .91 billion. That excluded the Upjohn unit, which Pfizer merged with Mylan to create Viatris (VTRS). The Upjohn business housed Pfizer's older drugs, including those facing generic competition.
That growth still lagged Pfizer's last year of strong gains in 2010. Then, sales jumped 34%.
Top sellers in 2020 included Ibrance, which generated .39 billion in sales, up 9%. Sales of blood thinner Eliquis popped 17% to .95 billion. But revenue from Prevnar 13 was flat at .85 billion.
Xeljanz, which is facing scrutiny for a recent post-marketing study, generated .44 billion, rising 9%. Vyndaqel and Vyndamax, which treat a condition that can cause heart failure, brought in
For 2021, analysts surveyed by FactSet call for Pfizer to earn .19 a share, minus some items, up about 89%. Analysts call for sales to pop 94% to .33 billion. Those numbers could change, though, after Pfizer announced its plan to buy Arena Pharmaceuticals (ARNA) for .7 billion. Arena is working on treatments for stomach, skin and heart problems.
In the third quarter, Pfizer raised its full-year outlook to billion to billion in sales and adjusted profit of .13-.18 per share. The company expects its Covid vaccine to bring in billion in sales this year and billion in 2022.
Pfizer Stock And Coronavirus Vaccine News
Pfizer and BioNTech are now working on a vaccine that could target omicron. They expect to launch it, if necessary, in March 2022. Meanwhile, they still plan to generate 4 billion doses of their original vaccine in 2022.
The FDA and CDC recently said all adults in the U.S. can get a Covid booster doses from Pfizer or Moderna (MRNA). Recipients of those vaccines are eligible six months after finishing their two-dose primary series.
Johnson & Johnson (JNJ) recipients can get their boosters two months after their one-shot vaccine.
Further, Pfizer and BioNTech said in mid-September that a smaller dose of their vaccine led to a strong antibody response in children age 5-11. The company expects data in younger children in the fourth quarter. The full FDA and CDC have now backed the pediatric vaccine for the 5-11 age group.
Pfizer stock also jumped in August after the FDA fully approved its Covid shot for people age 16 and up. The full approval will allow the vaccine to stay on the market after the pandemic ends. Pfizer and BioNTech can also change the price and market directly to consumers. The vaccine is also available under an emergency authorization for teens ages 12-15.
As part of the full approval for people ages 16 and up, Pfizer and BioNTech will be required to run testing to determine the prevalence of side effects known as myocarditis and pericarditis — inflammation of the heart and tissues surrounding it. They occur most frequently in young men.
But Pfizer stock fell in late June after the CDC noted there's a link between the Pfizer/BioNTech and Moderna vaccines and the inflammation. The European Medicines Agency also warned against the condition in mid-July.
New tests indicate the vaccine is 84% effective against Covid at six months. But it's still highly protective against hospitalizations and deaths.
Pfizer's oral antiviral pill also cut down on the risk of hospitalization and death by 89% in a key study when patients began the two-drug regimen within three days of symptoms appearing. When patients began the regimen within five days, the risk of severe outcomes was reduced by 88%.
In people with a standard risk of severe disease, the regimen cut down on hospitalization by 70%. There were no deaths among Paxlovid recipients.
Technical Analysis: PFE Stock Spikes And Then Falls
PFE stock overtook its buy point at 51.96 out of a cup base in late November. Shares have bounded into and out of their buy zone ever since. But Pfizer stock closed above its 5% chase zone on Dec. 14.
Bullishly, Pfizer stock remains above its 50-day moving average and 200-day line, according to MarketSmith.com.
(Related: Keep tabs on chart patterns by visiting IBD's MarketSmith.com.)
Shares of Pfizer have a Composite Rating of 98. The measure weighs a stock's key growth metrics against all other stocks. Leading stocks tend to have CRs of 95 or better, according to IBD Digital.
Pfizer stock also has a Relative Strength Rating of 95 out of a best-possible 99. The RS Rating measures a stock's 12-month running performance against all other stocks. That RS Rating means Pfizer stock ranks in the top 5% of all stocks in terms of performance.
The pharmaceutical company's EPS Rating, a measure of profitability, is a 80 out of a best-possible 99. The EPS Rating compares a stock's recent and longer-term earnings growth against all other stocks.
So, Is PFE Stock A Buy Right Now?
Based on CAN SLIM rules of investing, PFE stock isn't a buy right now. Shares are now above their 5% chase zone. Investors are encouraged to buy a stock when it rises above and is within 5% of its entry. In this case, that zone runs from 51.96-54.56.
The company is expected to report bullish growth in the fourth quarter, putting it in line with CAN SLIM advice. But that will mostly come on the back of its Covid vaccine.
It's important to keep tabs on how Pfizer stock performs as it develops a coronavirus vaccine with BioNTech. Results appear promising so far, but it will be important to see how the company deals with the growing prevalence of the delta and omicron variants.
To find the best stocks to buy and watch, check out IBD Stock Lists. Make sure to also keep tabs on stocks to buy or sell.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
Biotech Stocks To Watch And Pharma Industry News
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Watch IBD's Investing Strategies Show For Actionable Market Insights
Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists
PFE: Get the latest Pfizer stock price and detailed information including PFE news, historical charts and realtime prices.
|Date||Open||Close||Daily High||Daily Low|
Price change over selected period: 0% 0
Total Analysts: 36
Buy Ratings: 5 Neutral Ratings: 31 Sell Ratings: 0
Price *Price Target
Lowest: 36.00 Median: 44.78 Highest: 60.00
|Dividend Yield (in %)||3.59 %||3.75 %||3.86 %||4.03 %||4.18 %|
|Net Profit Adjusted||23,798||33,224||27,879||24,101||23,714|
|Net Profit (Adjusted)||24,415||40,249||28,289||19,190||18,130|
|EPS (Non-GAAP) ex. SOE||4.19||5.91||5.02||4.24||4.20|
|Cash Flow from Investing||-4,726||-4,298||-4,072||-4,068||-4,089|
|Cash Flow from Operations||25,624||32,971||27,240||27,010||26,546|
|Cash Flow from Financing||-11,551||-11,308||-12,653||-12,970||-13,319|
|Cash Flow per Share||4.45||6.90||5.81||4.07||4.52|
|Free Cash Flow||26,862||28,027||27,210||19,041||20,028|
|Free Cash Flow per Share||3.41||6.48||4.97||-||-|
|Book Value per Share||13.19||18.24||20.84||23.32||26.54|
|Research & Development Exp.||10,785||11,009||10,799||10,664||10,755|
|Selling, General & Admin. Exp.||12,058||12,502||12,101||11,951||11,973|
| Previous Quarter |
| Current Quarter |
| Next Quarter |
| Current Year |
| Next Year |
|No. of Analysts||14||16||7||20||20|
|Average Estimate||1.077 USD||0.907 USD||1.627 USD||4.191 USD||5.907 USD|
|Year Ago||0.720 USD||0.420 USD||0.930 USD||2.220 USD||4.191 USD|
|No. of Analysts||11||13||6||19||19|
|Average Estimate||22,576 USD||24,340 USD||24,513 USD||81,333 USD||93,653 USD|
|Year Ago||12,131 USD||11,684 USD||14,582 USD||41,908 USD||81,333 USD|
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
*Yield of the Respective Date
Add instrument to watchlist
Pfizer Inc. is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.
|The Vanguard Group, Inc.||7.99|
|Vanguard Group, Inc. (Subfiler)||7.78|
|SSgA Funds Management, Inc.||4.99|
|State Street Corp.||4.99|
|Capital Research & Management Co. (World Investors)||4.30|
|Wellington Management Co. LLP||3.94|
|Vanguard Total Stock Market Index Fund||2.83|
|BlackRock Fund Advisors||2.49|
|BlackRock Institutional Trust Co. NA||2.15|
|Vanguard 500 Index Fund||2.11|
|Geode Capital Management LLC||1.78|
|Vanguard Health Care Fund||1.25|
|Northern Trust Corp.||1.21|
|Washington Mutual Investors Fund||1.12|
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
|Albert Bourla||Chairman, Chief Executive & Operating Officer|
|Aamir Malik||Chief Business Innovation Officer & Executive VP|
|Sally Susman||Chief Corporate Affairs Officer & Executive VP|
|Alexander Roderick MacKenzie||Chief Development Officer & Executive VP|
|Frank A. D'Amelio||Chief Financial Officer & EVP-Global Supply|
|Payal Sahni Becher||Chief Human Resources Officer & Executive VP|
|Aida Habtezion||Chief Medical Officer|
|Mikael Dolsten||Chief Scientific Officer & Research President|
|Susan D. Desmond-Hellmann||Director|
|Rady A. Johnson||Executive VP, Chief Compliance & Risk Officer|
|Lidia L. Fonseca||Executive VP, Chief Digital & Technology Officer|
|Douglas M. Lankler||Executive Vice President & General Counsel|
|Angela Hwang||Group President-Biopharmaceuticals|
|Dan R. Littman||Independent Director|
|Scott Gottlieb||Independent Director|
|Susan J. Hockfield||Independent Director|
|Ronald E. Blaylock||Independent Director|
|Joseph J. Echevarria||Independent Director|
|James C. Smith||Independent Director|
|James Quincey||Independent Director|
|Suzanne Nora Johnson||Independent Director|
|Helen H. Hobbs||Independent Director|
|Bryan Dunn||Investor Relations Contact|
|Shantanu Narayen||Lead Independent Director|
|Susan Silbermann||President & General Manager-Pfizer Vaccines|
|Andy Schmeltz||President-US Oncology Business Unit|
|Margaret M. Madden||Secretary, Chief Governance Counsel & Senior VP|
|Jennifer B. Damico||Senior VP-Controller & Accounting Officer|
|Deborah Baron||Senior VP-Worldwide Business Development|
|Morris J. Birnbaum||Senior Vice President|
|Christopher J. Stevo||Senior Vice President|
|Gordon Loh||Senior Vice President-Corporate Audit|
|Hakan Sakul||Vice President & Head-Diagnostics|
|Eva Grut-Aandahl||Vice President, Head of EU Government Affairs|
|Barbara J. Dalton||Vice President-Worldwide Business Development|
|John DeYoung||Vice President-Worldwide Business Development|
|Monika A. Vnuk||Vice President-Worldwide Business Development|
Pfizer (PFE) Stock Falls After Dropping Pain Drug Shares of Pfizer (PFE) are down after the pharmaceutical company decided to discontinue its …
NEW YORK (TheStreet) -- Shares of Pfizer Inc. (PFE) - Get Pfizer Inc. Report are down by 0.21% to .05 after the pharmaceutical company notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize Remoxy Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone.
Pfizer said it will return all rights, including responsibility for regulatory activities, to Pain Therapeutics.
The decision to end the agreement followed an internal review of data from five recently completed studies to address the June 2011 rejection by the FDA, the company said.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Shares of Pain Therapeutics are down 53.61% to
Separately, TheStreet Ratings team rates PFIZER INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
"We rate PFIZER INC (PFE) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins, good cash flow from operations and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- The current debt-to-equity ratio, 0.49, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, PFE has a quick ratio of 2.03, which demonstrates the ability of the company to cover short-term liquidity needs.
- The gross profit margin for PFIZER INC is currently very high, coming in at 85.17%. It has increased significantly from the same period last year. Along with this, the net profit margin of 22.92% is above that of the industry average.
- Net operating cash flow has slightly increased to ,087.00 million or 6.71% when compared to the same quarter last year. In addition, PFIZER INC has also vastly surpassed the industry average cash flow growth rate of -53.12%.
- PFIZER INC's earnings per share declined by 10.0% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PFIZER INC increased its bottom line by earning
- You can view the full analysis from the report here: PFE Ratings Report
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
08-11-2020 · Why did Zoom’s stock crash today? Here’s what you need to know? Stock Market . The Dow Jones is up more than 5% today on two positive catalysts: The …
Zoom founder Eric Yuan poses in front of the Nasdaq building as the screen shows the logo of the ... [ ] video-conferencing software company Zoom after the opening bell ceremony on April 18, 2019 in New York City. (Photo by Kena Betancur/Getty Images)Getty Images
Why did Zoom’s stock crash today?
Here’s what you need to know?
The Dow Jones is up more than 5% today on two positive catalysts:
- The election of Joe Biden as the 46th president of the United States; and
- Pfizer PFE reporting positive results from a potential Covid-19 vaccine.
Pfizer, the pharmaceutical giant, said its clinical trial for a potential Coronavirus vaccine shows more than 90% efficacy in patients who receive a second dose after seven days.
“I think we can see light at the end of the tunnel,” Pfizer Chairman and CEO Dr. Albert Bourla said on CNBC today. “I believe this is likely the most significant medical advance in the last 100 years, if you count the impact this will have in public health, global economy.”
Pfizer’s stock soared 15% on the positive results. While there is no guarantee that Pfizer’s potential vaccine will receive final approval, former FDA commissioner Dr. Scott Gottlieb told CNBC the potential vaccine could be available widely by the third quarter of 2021, which implies next summer or early fall.
So, what does a vaccine have to do with Zoom?
Zoom stock crashes
Zoom, the video-conferencing software company, dropped nearly 20% today in early trading. Why? Zoom has been the go-to platform globally for the remote workforce. Think of it this way: Zoom is the poster child of the work from home movement. In April 2019, Zoom announced its IPO priced at per share, which implied a market capitalization of approximately .2 billion. This year, Zoom’s stock has risen by 600%.
Zoom stock falls: the drivers
Why has Zoom experienced explosive growth? The Covid-19 pandemic has fueled Zoom’s growth as more companies use Zoom’s platform for meetings and collaboration, while individuals use Zoom to stay in touch with friends and family. Social distancing rules and closed offices has led to a substantial increase in Zoom’s user base, financial performance and stock price.
A potential vaccine, if effective and if widely distributed, implies that Zoom’s growth and user base could slow. If more people return to in-person work or if social distancing rules are eased, or both, fewer people could use Zoom. While a 20% stock price drop is relatively small against the backdrop of year-to-date performance, it could be a sign of further downward pressure on Zoom’s share price if the vaccine receives regulatory and marketing approval.
Other stocks could benefit
Other stocks outside the healthcare sector could benefit with the approval of a potential vaccine. Here are some other sectors to watch for:
Essentially, any business that could thrive when in-person activity increases is a potential winner in this scenario. Conversely, work-from-home stocks like Peloton could suffer as more people may opt to exercise in a gym, rather than inside their home. That said, even with positive results in a relatively small sample size, there is no guarantee that Pfizer’s vaccine will be approved or will work on a wide-scale. This reality also could impact stock performance.
5 ways your student loans could change under Biden
Biden plans these 5 executive orders
Pfizer has split its stock a total of 5 times: July 1, 1983: a 2-for-1 split. April 1, 1991: a 2-for-1 split. July 3, 1995: a 2-for-1 split. July 1, 1997: a 2-for-1 split. July 1, 1999: a 3-for-1 ...
Pfizer Inc. "Form 10-K for the fiscal year ended December 31, 2020," Pages 1 & 2. Accessed Nov. 3, 2021.
Pfizer Inc. "Our People: The Journey." Accessed Nov. 3, 2021.
Statista. "Leading 10 biotech and pharmaceutical companies worldwide based on market capitalization as of 2021." Accessed Nov. 3, 2021.
Pfizer Inc. "Form 10-K for the fiscal year ended December 31, 2020," Page 20. Accessed Nov. 3, 2021.
Pfizer Inc. "ALBERT BOURLA, DVM, PH.D." Accessed Nov. 3, 2021.
S&P Dow Jones Indices. "S&P 500 Health Care: Data." Accessed Nov. 3, 2021.
Pfizer Inc. "Form 10-K for the fiscal year ended December 31, 2020," Page 51. Accessed Nov. 3, 2021.
Pfizer Inc. "PFIZER REPORTS THIRD-QUARTER 2021 RESULTS," Pages 1 & 2. Accessed Nov. 3, 2021.
Food and Drug Administration. "FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age." Accessed Nov. 3, 2021.
CNBC. "World Health Organization declares the coronavirus outbreak a global pandemic." Accessed Nov. 4, 2021.
Food and Drug Administration. "FDA Takes Key Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for First COVID-19 Vaccine." Accessed Nov. 4, 2021.
Food and Drug Administration. "Coronavirus (COVID-19) Update: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in Fight Against Pandemic." Accessed Nov. 4, 2021.
Food and Drug Administration. "FDA Approves First COVID-19 Vaccine." Accessed Nov. 4, 2021.
Pfizer Inc. "PFIZER-BIONTECH COVID-19 VACCINE COMIRNATY® RECEIVES FULL U.S. FDA APPROVAL FOR INDIVIDUALS 16 YEARS AND OLDER." Accessed Nov. 4, 2021.
Food and Drug Administration. "FDA Authorizes Booster Dose of Pfizer-BioNTech COVID-19 Vaccine for Certain Populations." Accessed Nov. 4, 2021.
Food and Drug Administration. "FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Children 5 through 11 Years of Age." Accessed Nov. 4, 2021.
Pfizer Inc. "DIVIDEND & SPLIT HISTORY." Accessed Nov. 3, 2021.
Pfizer Inc. "Form 10-Q for the quarterly period ended July 4, 2021," Page 1 (PDF). Accessed Nov. 4, 2021.
U.S. Food and Drug Administration. "FDA Approves First COVID-19 Vaccine." Accessed Nov. 11, 2021.
U.S. Food and Drug Administration. "PREVNAR 20." Accessed Nov. 11, 2021.
U.S. Food and Drug Administration. "Palbociclib (IBRANCE)." Accessed Nov. 10, 2021.
U.S. Food and Drug Administration. "ELIQUIS (apixaban) label." Accessed Nov. 10, 2021.
U.S. Food and Drug Administration. "XELJANZ® (tofacitinib) tablets, for oral use." Accessed Nov. 10, 2021.
Pfizer Inc. "Form 10-Q for the quarterly period ended July 4, 2021," Pages 34 & 35. Accessed Nov. 4, 2021.
Pfizer Inc. "PFIZER REPORTS THIRD-QUARTER 2021 RESULTS," Page 29. Accessed Nov. 4, 2021.
11-11-2020 · Pfizer CEO Albert Bourla cashed in on his company’s coronavirus vaccine breakthrough. The executive sold more than .5 million worth of Pfizer stock on …
Pfizer CEO Albert Bourla cashed in on his company’s coronavirus vaccine breakthrough.
The executive sold more than .5 million worth of Pfizer stock on Monday — the same day the drugmaker said its experimental COVID-19 shot was more than 90 percent effective, records show.
The groundbreaking development sent Pfizer’s share price surging as high as .99 that day, its highest level in more than a year. Bourla dumped more than 132,000 shares for .94 apiece, just five cents shy of that peak, according to a Tuesday securities filing.
Those shares amounted to more than 60 percent of Bourla’s Pfizer stock holdings, the filing shows. He still owns 78,273 shares directly plus another 3,539 that are held indirectly.
The filing says the sale had been arranged in advance under a so-called Rule 10b5-1 trading plan, which allows corporate executives to make predetermined stock transactions in compliance with insider trading laws. Bourla adopted the trading plan in August of this year, according to the document.
Bourla — who got more than million in total direct compensation from Pfizer last year, records show — wasn’t the only Pfizer honcho to make a well-timed trade on Monday.
Sally Susman, the Manhattan-based company’s executive vice president and chief corporate affairs officer, dumped more than 43,000 shares to the tune of about
Pfizer did not immediately respond to an email Wednesday morning seeking more details about the transactions.
Pfizer’s blockbuster Monday announcement inspired a broader stock market rally on hopes that the vaccine would help the global economy recover from the deadly coronavirus pandemic. The Dow Jones industrial average soared 834 points to post its best day since June, while Pfizer shares ended the day up about 7.7 percent at .20.
The company’s stock price climbed 0.7 percent to .95 in premarket trading as of 7:58 a.m. Wednesday following a roughly 1.3 percent loss Tuesday.
12-11-2020 · Pfizer's CEO sold .6 million worth of stock on Monday. The company says the stock sale was made as part of a preset plan. But NPR found irregularities about when the …
Albert Bourla, chairman and CEO of Pfizer, sold millions of dollars' worth of company stock on Monday as part of a preset plan. But NPR found irregularities about when the CEO entered into that plan.Zach Gibson/Bloomberg via Getty Images
The chairman and CEO of Pfizer, Albert Bourla, sold .6 million worth of stock in the pharmaceutical company on Monday. The sale took place on the same day Pfizer announced that its experimental coronavirus vaccine candidate was found to be more than 90% effective. The company's stock soared on the news.
Bourla sold the stock as part of a stock-trading plan that aims to shield corporate executives from allegations of illegal insider trading. But these plans have become increasingly controversial, and the issue has taken on added urgency given the billions of dollars the government has promised Pfizer if its vaccine meets the approval of federal regulators.
Bourla's sale of Pfizer stock was part of a trading plan set months in advance. Known as 10b5-1 plans, they essentially put stock trades on autopilot. Executives are supposed to adopt these plans only when they are not in possession of inside information that can affect a company's stock price — what's known as material nonpublic information.
The timing of the implementation of Bourla's plan, however, has raised questions about what the Pfizer CEO knew and when, and whether that may invite further scrutiny from federal regulators.
On Aug. 19, Bourla implemented his stock-trading plan, according to his disclosure to the Securities and Exchange Commission.
The next day, Aug. 20, Pfizer issued a press release featuring "additional Phase 1 safety and immunogenicity data" and confirming that Pfizer and its German partner, BioNTech, were "on track to seek regulatory review" for its vaccine candidate by October.
The financial news channels Fox Business, CNBC and Bloomberg all covered the August news, with CNBC noting that the stock appeared to be "moving sharply higher today on an optimistic vaccine timeline."
Daniel Taylor, an expert in insider trading and an associate professor of accounting at the Wharton School of the University of Pennsylvania, has closely monitored stock trades by executives at companies developing coronavirus vaccines. He told NPR that the close timing between the adoption of Bourla's stock plan and the press release looked "very suspicious."
"It's wholly inappropriate for executives at pharmaceutical companies to be implementing or modifying 10b5-1 plans the business day before they announce data or results from drug trials," Taylor said.
A spokesperson for Pfizer told NPR that the company did not believe the company's Aug. 20 press release contained material nonpublic information and that a stock plan administrator had previously vetted the implementation of the CEO's 10b5-1 plan. The spokesperson noted that the company had previously announced it expected to seek regulatory approval for its coronavirus vaccine candidate by October and that the August press release merely confirmed that timeline. In addition, the press release contained information from an academic study of Pfizer's vaccine, the spokesperson said, and the company did not control the timing or the content of that study.
"The sale of these shares is part of Dr. Bourla's personal financial planning and a pre-established (10b5-1) plan," Pfizer said in a statement. "Through our stock plan administrator, Dr. Bourla authorized the sale of these shares in February and renewed that authorization in August with the same price and volume terms."
The company spokesperson said Bourla's plan authorized stock sales when the share price hit a certain target.
Though Bourla's stock sale on Monday was significant, the company stated that he still held "approximately nine times his salary in Pfizer stock."
Taylor, of the Wharton business school, said the stock sales by Pfizer's CEO brought to mind similar concerns with another coronavirus vaccine-maker, Moderna. As NPR reported in September, multiple executives at Moderna adopted or modified their stock-trading plans just before key announcements about the company's vaccine. Those executives have sold tens of millions of dollars in Moderna stock, even though the company has not completed its vaccine trials.
"It's troubling to me that the general counsel or the internal controls of these companies would consider it legitimate to adopt a 10b5-1 plan one day before a major vaccine announcement," said Taylor. "If this isn't a wake-up call for the SEC and a wake-up call that we need to reform these 10b5-1 plans, I don't know what it is."
Billions of dollars in taxpayer funding are at stake in the race for a safe, effective and widely available coronavirus vaccine. The U.S. government has guaranteed roughly .5 billion to the development and manufacture of Moderna's vaccine, for example, and has promised to buy nearly billion worth of Pfizer's vaccine, if it receives regulatory approval.
Why Pfizer (PFE) Stock Is Down Today Pfizer (PFE) fell Wednesday after the pharmaceutical giant agreed to buy Baxter International's vaccine unit and a piece of a production facility for 5...
NEW YORK (TheStreet) -- Pfizer (PFE) - Get Pfizer Inc. Report fell Wednesday after the pharmaceutical giant agreed to buy Baxter International's vaccine unit and a piece of a production facility for 5 million.
The acquisition grants Pfizer access to Baxter's meningitis vaccine, NeisVac-C, and encephalitis vaccine, FSME-IMMUN, along with a part of Baxter's Austrian facility that produces the drugs. Pfizer expects to close the deal by the end of the year and does not expect it to affect the company's full-year results.
The stock was down 1.1% to .15 at 10:20 a.m.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Separately, TheStreet Ratings team rates PFIZER INC as a "buy" with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate PFIZER INC (PFE) a BUY. This is driven by several positive factors, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income."
Highlights from the analysis by TheStreet Ratings Team goes as follows:
- The current debt-to-equity ratio, 0.48, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, PFE has a quick ratio of 1.75, which demonstrates the ability of the company to cover short-term liquidity needs.
- Net operating cash flow has increased to ,935.00 million or 30.96% when compared to the same quarter last year. In addition, PFIZER INC has also vastly surpassed the industry average cash flow growth rate of -54.80%.
- PFIZER INC' earnings per share from the most recent quarter came in slightly below the year earlier quarter. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, PFIZER INC increased its bottom line by earning
- The gross profit margin for PFIZER INC is currently very high, coming in at 86.04%. Regardless of PFE's high profit margin, it has managed to decrease from the same period last year. Despite the mixed results of the gross profit margin, PFE's net profit margin of 20.61% compares favorably to the industry average.
- You can view the full analysis from the report here: PFE Ratings Report
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
June 25, 2021 -- Pfizer is suspending distribution of the anti- smoking treatment Chantix after heightened levels of the carcinogen N-nitrosodimethylamine (NDMA) were found in some lots of the...
June 25, 2021 -- Pfizer is suspending distribution of the anti-smoking treatment Chantix after heightened levels of the carcinogen N-nitrosodimethylamine (NDMA) were found in some lots of the pills.
The pharmaceutical company is also recalling some lots of Chantix that may have high levels of NDMA, Reuters reported.
Pfizer told Reuters the distribution pause was ordered out of abundance of caution while further testing is conducted. The FDA approved Varenacline, which is marketed as Chantix, in 2006.
"The benefits of Chantix outweigh the very low potential risks, if any, posed by nitrosamine exposure from varenicline on top of other common sources over a lifetime," Pfizer spokesperson Steven Danehy said in an email, according to Reuters.
The FDA has not issued a recall on Chantix. In Canada, however, health authorities on June 8 instituted a recall for Champix, the name under which the drug is sold in that nation.
The Chantix website says it’s a three-to-six-month treatment that helps people overcome the need to smoke tobacco. The website says more than 13 million people have been prescribed Chantix.
Other health concerns have been raised about Chantix, such as mental health side effects.
In 2016 ,however, researchers concluded Chantix did not appear to raise the risk of serious health disorders such as depression, anxiety, and suicidal thoughts.
04-11-2021 · Even though Moderna remains hugely profitable, its stock continued to tumble Friday, closing down another 16.5 percent, on the news that Pfizer’s …
In two days, Moderna’s stock price has fallen by more than 30 percent — from about 6 to 7 — wiping out more than billion in market value, a steep decline that followed lower projections for sales of the company’s COVID-19 vaccine and word from Pfizer that its pill to treat the virus performed spectacularly well in a study.
Before the pandemic, the Cambridge biotech’s shares were trading in the low range, but the stock soared on the success of its COVID-19 vaccine, reaching a high of 7 in August. That put the breakout biotech among the state’s largest corporations by market capitalization. But now as Moderna hits snags related to the making and delivery of its only product, and the field of COVID-19 therapeutics gets more crowded, investors are delivering something of a reality check.
In a quarterly earnings call Thursday, Moderna said it doesn’t expect to make as much money on its COVID-19 vaccine this year as originally projected. Instead of selling up to 1 billion doses and generating billion in revenue, it now expects to sell up to 800 million doses, lowering revenue projections to between billion and billion. The company’s share price dropped about 18 percent Thursday.
The company, which is now valued at about billion, also faces regulatory setbacks. The Food and Drug Administration is delaying a review of the vaccine’s use in children age 12 to 17 because of reports that in rare cases it could cause heart problems in adolescents. The FDA said the review process might not be completed before January. As a result, Moderna is holding off filing a request for authorization of its vaccine for even younger children.
Meanwhile, competitor Pfizer this week received the green light from the Centers for Disease Control and Prevention to begin offering its vaccine for children as young as 5 years old.
Mani Foroohar, an analyst in Boston with SVB Leerink who has long thought Moderna’s shares are overvalued, said he believes the company’s bubble is popping, mostly because Moderna is charging more than Pfizer for its vaccine, even though they are similarly effective.
“While the mRNA-1273 can effectively protect patients against COVID-19, it doesn’t protect Moderna shares from the basic laws of economics,” Foroohar said.
Even though Moderna remains hugely profitable, its stock continued to tumble Friday, closing down another 16.5 percent, on the news that Pfizer’s experimental antiviral pill for COVID-19 reduced the rate of hospitalization and death by nearly 90 percent. Analysts with Japanese investment banking and securities firm Mizuho Securities wrote that oral treatments such as Pfizer’s will “complement, not cannibalize, the vaccine.”
“We believe the vast majority of people who are willing and able to get vaccinated will still get vaccinated,” they wrote.
But Foroohar said that while antiviral pills do not directly compete with vaccines, since they treat rather than prevent the disease, they make the consequences of getting infected with COVID-19 much less dangerous.
“The implied value of a dose of a vaccine must go down,” he said. “The argument for Moderna’s aggressive pricing strategy starts to fall apart.”
What makes the situation worse for Moderna, he said, is that Pfizer could soon offer deals to governments that bundle vaccines and treatment pills.
Moderna reported .8 billion in vaccine revenue for the quarter, with .3 billion in earnings. Pfizer, meanwhile, beat estimates and recorded revenue of billion on its COVID-19 vaccine for the period, mostly through sales outside of the United States.
“Pfizer is the dominant player on vaccines, and now they can offer what appears to be the best-in-class oral antiviral,” Foroohar said.
Moderna did not respond to a request for comment.
Tony Mullin, a biotech human resources executive, said a stock drop following bad news can be “demoralizing” to employees, impacting retention even after a year filled with positive results. He said he knows a recruiter that has already heard from employees at Moderna about exploring other opportunities.
“For the hundreds of employees Moderna has hired over the last few months, many of them now have options that are underwater,” he said. Moderna grew its employee base during the pandemic to 2,400 people, double the total from a year ago.
“Most of them have only been part of a company when things are good,” Mullin said. “Now that things are not so rosy, it can really test the company’s leadership and strength of culture.”
Anissa Gardizy can be reached at [email protected] Follow her on Twitter @anissagardizy8.